These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 3361979)

  • 1. BEQUIV interactive microcomputer program for testing equivalence in two-group comparative bioavailability trials.
    Durisová M; Trnovec T
    Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):129-33. PubMed ID: 3361979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical aspects of comparative bioavailability trials.
    Westlake WJ
    Biometrics; 1979 Mar; 35(1):273-80. PubMed ID: 583027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KINPAK--a program for standardized pharmacokinetic analysis.
    Kaufmann B
    Methods Find Exp Clin Pharmacol; 1986 Oct; 8(10):615-24. PubMed ID: 3784699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possibilities of the application of regression analysis and analysis of variance. II. Assessment and comparison of acute toxicity: presentation and practical application of the interactive computer program "LD50-MORTALITY".
    Arambasić MB; Pitić LJ; Jeremić D; Adnadjević D
    Boll Chim Farm; 2002; 141(4):290-8. PubMed ID: 12426817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Review and use of decision rules for bioequivalence trials].
    Nicolas P; Tod M; Petitjean O
    Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint equivalence of means and variances of two populations.
    Grieve AP
    J Biopharm Stat; 1998 Jul; 8(3):377-90. PubMed ID: 9741854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials.
    Hauck WW; Anderson S
    J Pharmacokinet Biopharm; 1984 Feb; 12(1):83-91. PubMed ID: 6747820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of testing times and critical values in sequential equivalence testing.
    Müller HH; Schäfer H
    Stat Med; 1999 Jul; 18(14):1769-88; discussion 1789. PubMed ID: 10407247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of new bioavailability parameters in the bioequivalence testing of antimicrobial agents.
    Wessels JC; Koeleman HA; Steyn HS; Ellis SM
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):542-6. PubMed ID: 8294166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computerized calculation of biological potency: presentation of the interactive computer program "POTENCY" (assays: "2 + 2" doses, "3 + 3" doses, "twin cross-over assay" and "probit analysis" ("2 + 2" doses).
    Arambasić MB
    Boll Chim Farm; 2001; 140(6):433-9. PubMed ID: 11822234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative bioavailability study of two formulations of risperidone available in the Chilean market].
    Gaete LE; Solís J; Venegas P; Carrillo MJ; Schatloff O; Saavedra I
    Rev Med Chil; 2003 May; 131(5):527-34. PubMed ID: 12879814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A SAS/IML program for implementing the modified Brown-Forsythe procedure in repeated measures designs.
    Vallejo G; Moris J; Conejo NM
    Comput Methods Programs Biomed; 2006 Sep; 83(3):169-77. PubMed ID: 16934362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers.
    Yamaoka K; Tanaka H; Okumura K; Yasuhara M; Hori R
    J Pharmacobiodyn; 1986 Feb; 9(2):161-73. PubMed ID: 3754893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of non-compliance on intent-to-treat analysis of equivalence trials.
    Sheng D; Kim MY
    Stat Med; 2006 Apr; 25(7):1183-99. PubMed ID: 16220491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalence trials: methodologic analysis.
    Carneiro A
    Rev Port Cardiol; 2003 Sep; 22(9):1125-39. PubMed ID: 14655314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
    Panhard X; Mentré F
    Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.